This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • CAPTIVATE study shows an Imbruvica + Venclexta com...

CAPTIVATE study shows an Imbruvica + Venclexta combination has potential for remission in CLL/SLL patients.- AbbVie

Read time: 1 mins
Published:10th Jun 2021
AbbVie announced new data from the Phase II CAPTIVATE (PCYC-1142) study investigating Imbruvica (ibrutinib) in combination with Venclexta (venetoclax), an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) during an oral presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7501).

The ibrutinib and venetoclax cohort met its primary endpoint of complete response (CR) rate of 56% (95% CI 48-64) among patients without del(17p), 70 years old or younger and with 27.9 months of follow up. This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001). the cr rate was consistent across all patients in the study including high-risk cll patient groups. furthermore, 24-month progression free survival (pfs) and overall survival (os) were 95% and 98%, respectively. while the interim data reported for the phase ii captivate study are promising, a larger-scale phase iii study is also essential, which commenced in april 2018 in the treatment-naïve patient population, but excludes those with high-risk 17p deletion and or p53 mutation. the superior efficacy that has so far been reported for imbruvica + venclexta, which may ultimately suggest a curative capacity for the regimen, as well as its potential as a time-limited therapy that would reduce treatment-related toxicities in patients, all contribute to the optimistic outlook for the combination therapy in cll.></0.0001).>

Condition: CLL/SLL
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights